Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Best wishes for the holiday season from the Center for Women's Mental Health.
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Every week we review the most recent publications in women’s mental health.
The largest study to date observes no increase in risk of autism or ADHD in children with prenatal exposure to benzodiazepines.
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
Cannabis use in preganat and menopausal women, COVID and worse pregnancy outcomes but some antivirals appear to be safe, new fertility trachers.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.